The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer

Medical Oncology

Volumn 20, Issue 3, 2003, Pages 221-231

  Cocquyt, Veronique F ^a   Schelfhout, Vera R ^a   Blondeel, Phillip N ^a   Depypere, Herman T ^a   Daems, Kristof K ^b   Serreyn, Rudolphe F ^a   Praet, Marleen M ^a   Van Belle, Simon J P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Biological markers; Breast cancer; Preoperative chemotherapy

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CATHEPSIN D; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CATHEPSIN D; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141860027     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:3:221     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352:930-942.
2. Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with breast cancer. J Clin Oncol 1998; 16:2672-2685.
3. Kuerer H, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
4. Bonadonna G, et al. Primary chemoterapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16:93-100.
5. Goldhirsch A, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90:1601-1608.
6. Goldhirsch A, Glick J, Gelber R, Coates A, Senn H. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19:3817-3827.
7. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000; 11:647-663.
8. Levine M, et al. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16:2651-2658.
9. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-1481.
10. Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37:S11-S17.
11. Jacobs TW, Gown AM, Yaziji H, Barnes M, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17:1974-1982.
12. Rozan S, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Intl J Cancer 1998; 79:27-33.
13. Tetu B, et al. Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Intl J Cancer 1993; 55:429-435.
14. Chang J, et al. Biologic markers as predictors of clinical outcome from systemic chemoendocrine therapy for primary operable breast cancer. J Clin Oncol 1999; 17:3058-3063.
15. Slamon D, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344:783-792.
16. Yamauchi H, Stearns V, Hayes D. When is a tumormarker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-2356.
17. Buchholz T, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002; 20:17-23.
18. Van der Hage J, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224-4237.
19. Hutcheon AW, et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial. 24th Annual San Antonio Breast Cancer Symposium, December 10-13, 2001; abstract 506.
20. Colleoni M, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000; 11:1057-1059.
21. Daidone M, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer (Pred Oncol) 1999; 84:580-586.
22. MacGrogan G, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST γ. Br J Cancer 1996; 74:1458-1465.
23. Makris A, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3:593-600.
24. Allred DC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200-206.
25. Ferreira CG, Tolis C, Giaccone G. P53 and chemosensitivity. Ann Oncol 1999; 10:1011-1021.
26. Makris A, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3:593-600.
27. Geisler S, et al. Influence of TP53 gene alterations and c-erbB2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512.
28. Aas T, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-813.
29. Muss HB, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Eng J Med 1994; 330:1260-1266.
30. Gusterson BA, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10:1049-1056.
31. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 1992; 31:125-130.
32. Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-11/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 1990; 4:1327-1335.
33. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997; 76:917-922.
34. Daidone MG, et al. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995; 61(3):301-305.
35. Frassoldati A, et al. Changes in biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1997; 44:185-192.